<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247805</url>
  </required_header>
  <id_info>
    <org_study_id>A1481293</org_study_id>
    <secondary_id>EudraCT 2010-023521-38</secondary_id>
    <nct_id>NCT01247805</nct_id>
  </id_info>
  <brief_title>A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions</brief_title>
  <official_title>A Pivotal Randomised, Open-Label 3-Way Crossover Study To Demonstrate Bioequivalence Of The Sildenafil Citrate Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil Citrate 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for the trial is that the Sildenafil Citrate Powder for Oral Suspension (10
      Mg/ml) bioequivalent to the Revatio 20 Mg IR tablet in Healthy Volunteers and the Sildenafil
      Citrate 10 Mg immediate release (IR) tablet is bioequivalent to the Revatio 20 Mg IR tablet
      in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC0-T) of sildenafil plasma concentrations from time zero to the time T of last measurable concentration.</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum sildenafil plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, AUC of sildenafil from time zero to time infinity. AUCinf = AUC0-T+AUCextrapolated</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC%extrapolated of sildenafil.</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - time at which maximum sildenafil plasma concentration occurs</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From FSFV to LSLV, up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal half-life of sildenafil.</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Pulmonary Arterial Hypertention</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revatio: 1 x 20 mg IR oral tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 10 mg sildenafil citrate IR oral tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>Single oral dose of 1 x 20 mg IR oral tablet.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil citrate</intervention_name>
    <description>single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Healthy male/female subjects between the ages of 18 and 55 years, inclusive. Healthy is
        defined as no clinically relevant abnormalities identified by a detailed medical history,
        full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG
        and clinical laboratory tests.

        2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        3. An informed consent document signed and dated by the subject or a legally acceptable
        representative.

        4. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
        laboratory tests, and other study procedures.

        Exclusion Criteria:

          1. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, ocular
             or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal
             allergies at the time of dosing) disease or clinical findings at Screening.

          2. History of febrile illness within 5 days prior to the first dose.

          3. A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481293&amp;StudyName=A%20Pivotal%20Bioequivalence%20Study%20Between%20The%20Sildenafil%20Powder%20For%20Oral%20Suspension%20%2810%20Mg/Ml%29%20And%20The%20Sildenafil%2010%20Mg%20Immediate%20Relea</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Powder for oral suspention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

